explore -WSS

explore

author：focus 2025-10-02 00:53:35 - browse：648

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： SCOTUS questions limit to govt efforts to fight misinformation

leisure time

WSS

Experimental asthma app from Apple and Anthem shows promise

Ventyx halts psoriasis drug development after lackluster trial results

Future doctors should be trained to promote social change

Methadone treatment changes are coming. Do they go far enough?

Ohio still needs to do more to protect the right to abortion

UnitedHealth increases loan offers after Change Healthcare outage

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Sports medicine is finally prioritizing gender equality

Weight loss drugs should be covered by insurers, AMA says

State Dept. review finds Biden bears some blame for Afghanistan failures

After decades in use, heart stents finally beat placebo

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Novavax promises a turnaround & Lilly roils the obesity market

NIH chief: government has fallen behind pharma on clinical trials

How one medical school became remarkably diverse

U.K. researchers warn about biases in medical devices, algorithms

Wikipedia

UnitedHealth increases loan offers after Change Healthcare outage

Intermittent fasting comes with a heart risk? Not so fast

U.K. researchers warn about biases in medical devices, algorithms

Methadone treatment changes are coming. Do they go far enough?

UnitedHealth sued over use of algorithm in Medicare Advantage plans

CVS, Rite Aid closures threaten to worsen pharmacy deserts

focus

leisure time

hotspot

focus